Physician profile
Stephen E Syler
NPI 1801882857
$8,086.43
in general payments reported to CMS, 2019-2025
43 companies · $1,403 in 2025
The $1,403 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,029 · 2020: $652 · 2021: $926 · 2022: $1,059 · 2023: $1,430 · 2024: $1,587 · 2025: $1,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,420.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,162.67 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,082.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $796.68 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Amgen INC. | $569.77 | 2019-2025 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $536.35 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $376.50 | 2019-2021 | |
| Lilly USA, LLC | $363.74 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $296.53 | 2023-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $264.17 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Takeda Pharmaceuticals U.S.A., INC. | $236.73 | 2019-2024 | Trintellix |
| Axsome Therapeutics, INC. | $218.94 | 2024-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.54 | 2019-2025 | Jardiance |
| Corium, LLC | $164.46 | 2023-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $163.79 | 2024-2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $127.36 | 2024-2025 | Dyanavel Xr |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Syler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.